312 related articles for article (PubMed ID: 30947117)
1. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy.
Xu J; Wang H; Xu L; Chao Y; Wang C; Han X; Dong Z; Chang H; Peng R; Cheng Y; Liu Z
Biomaterials; 2019 Jul; 207():1-9. PubMed ID: 30947117
[TBL] [Abstract][Full Text] [Related]
2. Nanoscale Coordination Polymer Based Nanovaccine for Tumor Immunotherapy.
Zhao H; Xu J; Li Y; Guan X; Han X; Xu Y; Zhou H; Peng R; Wang J; Liu Z
ACS Nano; 2019 Nov; 13(11):13127-13135. PubMed ID: 31710460
[TBL] [Abstract][Full Text] [Related]
3. Highly Enhanced Antitumor Immunity by a Three-Barreled Strategy of the l-Arginine-Promoted Nanovaccine and Gene-Mediated PD-L1 Blockade.
Hu Y; Lin L; Chen J; Hao K; Zhang S; Guo X; Guo Z; Tian H; Chen X
ACS Appl Mater Interfaces; 2020 Sep; 12(37):41127-41137. PubMed ID: 32808767
[TBL] [Abstract][Full Text] [Related]
4. Cell-Penetrating Peptide Enhanced Antigen Presentation for Cancer Immunotherapy.
Wu H; Zhuang Q; Xu J; Xu L; Zhao Y; Wang C; Yang Z; Shen F; Liu Z; Peng R
Bioconjug Chem; 2019 Aug; 30(8):2115-2126. PubMed ID: 31339694
[TBL] [Abstract][Full Text] [Related]
5. Orchestrated Cytosolic Delivery of Antigen and Adjuvant by Manganese Ion-Coordinated Nanovaccine for Enhanced Cancer Immunotherapy.
Gao ZL; Xu W; Zheng SJ; Duan QJ; Liu R; Du JZ
Nano Lett; 2023 Mar; 23(5):1904-1913. PubMed ID: 36801829
[TBL] [Abstract][Full Text] [Related]
6. Cooperating minimalist nanovaccine with PD-1 blockade for effective and feasible cancer immunotherapy.
Jiang M; Zhao L; Cui X; Wu X; Zhang Y; Guan X; Ma J; Zhang W
J Adv Res; 2022 Jan; 35():49-60. PubMed ID: 35003793
[TBL] [Abstract][Full Text] [Related]
7. Highly enhanced cancer immunotherapy by combining nanovaccine with hyaluronidase.
Guan X; Chen J; Hu Y; Lin L; Sun P; Tian H; Chen X
Biomaterials; 2018 Jul; 171():198-206. PubMed ID: 29698869
[TBL] [Abstract][Full Text] [Related]
8. A generally minimalist strategy of constructing biomineralized high-efficiency personalized nanovaccine combined with immune checkpoint blockade for cancer immunotherapy.
Zhang S; Feng Y; Meng M; Li Z; Li H; Lin L; Xu C; Chen J; Hao K; Tang Z; Tian H; Chen X
Biomaterials; 2022 Oct; 289():121794. PubMed ID: 36113330
[TBL] [Abstract][Full Text] [Related]
9. Multi-signaling pathway activation by pH responsive manganese particles for enhanced vaccination.
Lv X; Huang J; Min J; Wang H; Xu Y; Zhang Z; Zhou X; Wang J; Liu Z; Zhao H
J Control Release; 2023 May; 357():109-119. PubMed ID: 36738971
[TBL] [Abstract][Full Text] [Related]
10. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.
Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D
J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656
[TBL] [Abstract][Full Text] [Related]
11. Antigen-Conjugated Silica Solid Sphere as Nanovaccine for Cancer Immunotherapy.
Dong Y; Gao J; Pei M; Wang X; Zhang C; Du Y; Jiang Y
Int J Nanomedicine; 2020; 15():2685-2697. PubMed ID: 32368049
[TBL] [Abstract][Full Text] [Related]
12. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
[TBL] [Abstract][Full Text] [Related]
13. Engineering ApoE3-incorporated biomimetic nanoparticle for efficient vaccine delivery to dendritic cells via macropinocytosis to enhance cancer immunotherapy.
Zhou S; Huang Y; Chen Y; Liu S; Xu M; Jiang T; Song Q; Jiang G; Gu X; Gao X; Chen J
Biomaterials; 2020 Mar; 235():119795. PubMed ID: 32014739
[TBL] [Abstract][Full Text] [Related]
14. Nanovaccine Incorporated with Hydroxychloroquine Enhances Antigen Cross-Presentation and Promotes Antitumor Immune Responses.
Liu J; Liu X; Han Y; Zhang J; Liu D; Ma G; Li C; Liu L; Kong D
ACS Appl Mater Interfaces; 2018 Sep; 10(37):30983-30993. PubMed ID: 30136844
[TBL] [Abstract][Full Text] [Related]
15. Dual-responsive nanovaccine for cytosolic delivery of antigens to boost cellular immune responses and cancer immunotherapy.
Sui Y; Li J; Qu J; Fang T; Zhang H; Zhang J; Wang Z; Xia M; Dai Y; Wang D
Asian J Pharm Sci; 2022 Jul; 17(4):583-595. PubMed ID: 36101894
[TBL] [Abstract][Full Text] [Related]
16. Tumor Lysate-Loaded Lipid Hybrid Nanovaccine Collaborated with an Immune Checkpoint Antagonist for Combination Immunotherapy.
Hu X; Wu T; Qin X; Qi Y; Qiao Q; Yang C; Zhang Z
Adv Healthc Mater; 2019 Jan; 8(1):e1800837. PubMed ID: 30506847
[TBL] [Abstract][Full Text] [Related]
17. "Minimalist" Nanovaccine Constituted from Near Whole Antigen for Cancer Immunotherapy.
Wang K; Wen S; He L; Li A; Li Y; Dong H; Li W; Ren T; Shi D; Li Y
ACS Nano; 2018 Jul; 12(7):6398-6409. PubMed ID: 29927574
[TBL] [Abstract][Full Text] [Related]
18. Delivery of antigen using a novel mannosylated dendrimer potentiates immunogenicity in vitro and in vivo.
Sheng KC; Kalkanidis M; Pouniotis DS; Esparon S; Tang CK; Apostolopoulos V; Pietersz GA
Eur J Immunol; 2008 Feb; 38(2):424-36. PubMed ID: 18200633
[TBL] [Abstract][Full Text] [Related]
19. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy.
Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q
ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639
[TBL] [Abstract][Full Text] [Related]
20. Acid-Ionizable Iron Nanoadjuvant Augments STING Activation for Personalized Vaccination Immunotherapy of Cancer.
Chen F; Li T; Zhang H; Saeed M; Liu X; Huang L; Wang X; Gao J; Hou B; Lai Y; Ding C; Xu Z; Xie Z; Luo M; Yu H
Adv Mater; 2023 Mar; 35(10):e2209910. PubMed ID: 36576344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
